Section Review: Central & Peripheral Nervous Systems: Macromolecular drug delivery to the CNS with protein carriers

References

• FRIEDEN PM: Delivery of therapeutic proteins across the blood-brain barrier. In: Drug Delivery and Targeting Sys-tems. Conference Documents. London (November 22–23, 1993).
   Google Scholar
• BANKS WA, TUSTIN AJ, BARRERA CM: Delivering Peptides to the Central Nervous system: Dilemmas and Strate-gies. Pbarmac. Res. (1991) 8(11):1345–1350.
   PubMed Web of Science ®Google Scholar
• PARDRIDGE WM: New approaches to drug delivery through the blood-brain barrier. TiBTECJI (1994) 12:239–245.
   PubMed Web of Science ®Google Scholar
• ZLOKOVICH By, GHISO J, MACKICH JB et al.: Blood-brain transport of circulating Alzheimer's amykild13. Biocbem. Biophys. Res. Comm. (1993) 197(3)1034–1040.
   Google Scholar
• PODUSLO JF, CURRAN GL, BERG CT: Macromolecular permeability across the blood-nerve and blood-brain barriers. Proc. Natl. Acad. Sci. USA (1994) 91:5705-5706. The paper critically reviews established opinions on the transport of macromolecules across blood-brain and blood-nerve barriers which was considered as non-existent and nonphysiological. By choosing different protein markers and methods of study, a low but detectable penetration of proteins as large as immunoglobulin has been de-tected.
   Google Scholar
• BLACK KL: Biochemical opening of the blood-brain barrier. Adv. Drug Deily. Rev. (1995) 15(1-3):37–52.
   Web of Science ®Google Scholar
• TUSZYNSKI MH, U HS, YOSHIDA K, GAGE FH: Recombi-nant human nerve growth factor infusions prevent cholinergic neuronal degeneration in the aduh primate brain. Ann. Neurol. (1991) 30:625–626.
   PubMed Web of Science ®Google Scholar
• SAFFRAN BN: Should intracerebroventricular nervegrowth factor be used in the treatment of Alzheimer's disease? Perspect. Biol. Med. (1992) 35(4):471–486.
   Google Scholar
• MEDTRONICS, INC.: Medtronlcs drug delivery ventures.Company Communication (November 2, 1995).
   Google Scholar
• HARBAUGH RE, ROBERTS DW, COOMBS DW, SAUNDERS RI, REEDER TM: Primary report: intracranialcholinergic drug infusion in patients with Alzhehner's' disease. Neurosurgery (1984) 15:514-518. An important paper to understand the construction and performance of intracranial drug delivery systems as well as safety issues accom-panying their use in humans with AD.
   Google Scholar
• TUSZYNSKI MH, GAGE PH: Potential use of neurotropic agents in the treatment of neurodegenerative disorders. Acta Neurobiol. (1990) 50:311–322.
   PubMed Web of Science ®Google Scholar
• SQUINT° SP, M.ADRI JA, KENNEDY S, SPRINGHORN J: The ENCEL system: a somatic cell protein delivery system.In Vivo (1994) 8:771-780. An excellent synopsis of the ENCEL drug delivery technology, developed by Alexion Pharmaceuticals, which is based on grafting genetically modified capillary endothelial somatic cells.
   Google Scholar
• AEBISCHER P, KATO AC: Treatment of amyotrophic lateral sclerosis using a gene therapy approach. Eur. Neurol. (1995) 35:65–68.
   PubMed Web of Science ®Google Scholar
• AEBISHER P, SCHLEUP M, DEGLON M et al.: Intrathecaldelivery of CNTF using encapsulated genetically modi-fied xenogeneic cells in arnyotrophic lateral sclerosis patients. Nature Medicine (1996) 2:696–699.
   PubMedGoogle Scholar
• PARDRIDGE WM: Peptide Drug Delivery to the Brain. RavenPress, New York (1991).
   Google Scholar
• BICKEL U, YOSHIKAWA T, LANDAW EM, FAULL RE, PAR-DRIDGE WM: Pharmaeologic effects in vivo in brain by vector mediated peptide drug delivery. Proc. Natl. Acad. Sci. USA (1993) 90:2618–2622.
   PubMed Web of Science ®Google Scholar
• BICKEL U, YOSHIKAWA T, PARDRIDGE WM: Delivery ofpeptides and proteins through the blood-brain barrier. Adv. Drug Deliv. Rev. (1993) 10:205–245.
   Web of Science ®Google Scholar
• PARDRIDGE WM, KANG YS, BUCIAK JL: Transport ofhuman recombinant brain derived neurotrophic factor (BNDF) through the rat blood-brain barrier in vivo using vector-mediated peptide drug delivery. Pbarmac. Res. (1994) 11(5):738–746.
   PubMed Web of Science ®Google Scholar
• BONGARTZ J-P, AUBERTIN A-M, MILHAUD PG, LEBLEU B:Improved biological activity of antisense oligonu-cleotides conjugated to a fusogenic peptide. Nucleic Acids Res. (1994) 22:4681–4688.
   PubMed Web of Science ®Google Scholar
• PARDRIDGE WM, BUCIAK JL, YOSHIKAWA T: Transportof recombinant CD4 through the rat blood-brain bar-rierin vivo.J.Pbarmacol.E:cp. Ther. (1992) 26(3):1175–1180.
   Google Scholar
• BEAUDE P, DELACOUR A, BIZZINI B, DOMUADO D, REMYM-H: Retrograde transport of an axogeneous enzyme covalently linked to B-III3 fragment of tetanus toxin. Biocbem. J. (1990) 271:87–91.
   PubMed Web of Science ®Google Scholar
• DOBRENIS K, JOSEPH A, RATTAZI MC: Neuronal lysoso- mal enzyme replacement using fragment C of tetanus toxin. Proc. Natl. Acad. Sci. USA (1992) 89:2297-2301. A pioneering investigation on using protein carrier based on a receptor binding domain of tetanus toxin for efficient delivery of human hexosaminidase to neuronal lysosomes to achieve enzyme replacement in neurodegenerative lysosomal storage disease.
   Google Scholar
• NIEMAN H: Molecular biology of clostridia' neurotox-ins. In: Sourcebook of Bacterial Protein Toxins. Academic Press, New York, London (1991):303–348. An excellent review on the molecular biology of botulinum and tetanus neurotoxins and mechanisms of their uptake by neuronal cells.
   Google Scholar
• PASECHNIK VA, SHONE CC, HAMBLETON P: Purificationof bacterial exotoxins. Bioseparation (1993) 3:267–283.
   Google Scholar
• BIZZINI B, STOECICEL K, SCHWAB M: An antigenic polypepticle fragment isolated from tetanus toxin: chemical characterisation, binding to gangliosides and retrograde axonal transport in various neuron systems. J. Neurocbem. (1977) 28:529–542.
   PubMed Web of Science ®Google Scholar
• BIZZINI B, GROB P, GLICKSMAN MA, ACKERT K: Use ofthe BIZ tetanus toxin derived fragment as a specific neuropharmacological transport agent Brain Res. (1980) 193:221–227.
   Google Scholar
• SENANAYAKE N, ROMAN G: Disorders of neuromuscular transmission due to natural environmental toxins. J. Neurological Sci. (1992) 107:1-13. A review article which describes how neurotoxins, 'les scalpels phannacologiques', contribute to understanding neuromuscular junction and neuromuscular transmission. The paper brings the clinical and pathophysiological viewpoints on the naturally occur-ring neurotoxins of animal, plant and bacterial origin.
   Google Scholar
• THORNE RG, EMORY CR, ALA TA, FREY WH, II: Quantita- tive analysis of the olfactory pathway for drug delivery to the brain. Brain Res. (1995) 692:278–282.
   PubMed Web of Science ®Google Scholar
• DOMB A, MANIAR M, BOGDANSKY S, CHASIN M: Drug delivery to the brain with polymers. Crit. Rev. Tber. Drug Carr. Systems (1991) 8W:1–17.
   Google Scholar
• SNYDER EY: Grafting immortalised neurons to the CNS. Curr. Opin. Neurobiology (1994) 4:742-751. A review of the current trends in a new rapidly developing area encompassing neural progenitor cell biology and restorative neurol-ogy. In the context of the present review, the most interesting section is the presentation of developments in immortalised (by viral vectors as well as by chronic exposure to neurotrophins) and genetically modified primary neuronal progenitors for grafting and gene ther-apy.
   Google Scholar
• ALKERMES, INC.: Alkermes presentation at New York Society of Security Analysts. Business Wire (March 13, 1995).
   Google Scholar
• REGENERON, INC.: Business Wire (June 26, 1995).
   Google Scholar
• HOWARD RS: Neurology, recent advances. Br. J. Med. (1994) 309:392–395.
   PubMed Web of Science ®Google Scholar
• JINNAH HA, FRIEDMAN T: Gene therapy and the brain.Br. Med. Bull. (1995) 511:138–148.
   Google Scholar
• HAMMANG JP, EMERICH DF, WINN SR et al.: Delivery of neurotrophic factors to the CNS using encapsulated cells: developing treatments for neurodegenerative dis-eases. Cell Transplantation (1995) 4\(Suppl. 1):S27–S28.
   Google Scholar
• HALLRVELL B: Reactive oxygen species and the central nervous system. J. Neurochemistry (1992) 59:1609–1623.
   PubMed Web of Science ®Google Scholar
• BARINAGA M: Neurotrophic factors enter the clinic. Science (1994) 264:772–774.
   PubMed Web of Science ®Google Scholar
• BROWN DR, SCHMIDT B, KRETZSCHMAR HA: Role of microglia and host prion disease in neurotoxicity of a prion protein fragment. Nature (1996) 380(6752):345–347.
   PubMedGoogle Scholar
• ROSENBERG MB, FRIEDMAN T, ROBERTSON RS et al.:Grafting genetically modified cells to the damaged brain: restorative effects of NGF expression. Science (1988) 242:1575–1578.
   PubMed Web of Science ®Google Scholar
• LINDSAY RM: Trophic protection of motor neurons:clinical potential in motor neuron diseases. J. Neurol. (1994) 24:S1–S8.
   Google Scholar
• RAIVICH G, HELLWEG R, KREUTZBERG GW: NGF receptor mediated reduction in axonal NGF uptake and retro-grade transport following sciatic nerve injury and dur-ing regeneration. Neuron (1991) 7(1):151–164.
   PubMed Web of Science ®Google Scholar
• BRACHOVA L, LUE LF, WEBSTER S et al.: Complement activation and 13-amyloid-mediated neurotoxicity in Alzheimer disease. Res. Immunol. (1992) 143(6):624–630.
   PubMedGoogle Scholar
• ROGERS J, SCHULZ J, ROSENBERG S: Trophic factors andtheir receptors in the CNS. Ann. Rep. Med. Chem. (1992) 27:41–48.
   Google Scholar
• SWIFF AJ, COLLINS TS, BUGELSKI P, WINKELSTEIN JA:Soluble human complement receptor type 1 inhibits complement mediated host defense. din. Diagn. Lab. Immunol. (1994) 1(9:585–589.
   PubMedGoogle Scholar
• FRANCIES JW, HOSIER BA, BROWN RH, Jr., FISHMAN PS:CuZn superoxide dismutase (SOD-1):tetanus toxin frag-ment C hybrid protein for targeted delivery of SOD-1 to neuronal ceas. J. Biol. Chem. (1995) 270(25):15434–15442.
   PubMed Web of Science ®Google Scholar
• HARBAUGH RE: Intracranial drug administration in Alzheimer disease. Psychopharmacol. Bull. (1986) 22:106–109.
   PubMed Web of Science ®Google Scholar
• HARBAUGH RE: Intracerebroventricular cholinergic drug administration in Alzheimer's disease: prelimi-nary results of a double-blind study J. Neural Transm. (1987) 24(Suppl.):271–277.
   Google Scholar
• FREESE A, SABEL BA, SALTZMAN WM, DURRING M J,LANGER R: Controlled release of dopamine from a polymeric brain implant: in vitro characterisation. Exp. Neural. (1989) 103:234–238.
   PubMed Web of Science ®Google Scholar
• GAGE FH, ARMSTRONG DM, WILLIAMS LR, VARON S: Morphologic response of axotomiz.ed septal neurons to nerve growth factor. J. Comp. Neurol. (1988) 269:147–155.
   PubMedGoogle Scholar
• THOENEN H: The changing scene of neurotropic fac-tors. TINS (1991) 14(5):165–170.
   PubMed Web of Science ®Google Scholar
• SPELLBERG B, PRASAD S, CABELLOS C et al.: Penetration of the blood-brain barrier: enhancement of drug deliv-ery and imaging by bacterial glycopeptides. J. Exp. Med. (1995) 182:1037-1044. An important paper on methods of biochemical opening of the BBB. A comparison of results obtained with bacterial glycopeptides and the bradykinin analogue RMP-7 is provided.
   Google Scholar
• HEARTLEIN MW, ROMAN VA, JIANG J-L etal.: Long-term production and delivery of human growth hormone. Proc. Natl. Acad. Sci. USA (1994) 91:10967–10971.
   Google Scholar
• WINN SR, HAMMANG JP, EMERICH DF etal.: Polymer-en-capsulated cells genetically modified to secrete human nerve growth factor promote the survival of axoto-mixed septal cholinergic neurons. Proc. Natl. Acad. Sci. USA (1994) 91:2324–2328.
   Google Scholar
• KOLBERG R: Gene-transfer virus contaminant linked to monkey' cancer. J. A7H Res. (1992) 4:43-44. A disquieting discovery in primates of cancer linked to retrovirus-mediated gene-transfer into bone-marrow stem cells to treat blood-born diseases.
   Google Scholar
• EMERICH DF, WINN SR, HARPER J et al.: Implants of polymer-encapsulated human NGF-secreting cells in the non-human primate: rescue and sprouting of de-generating cholinergic basal forebrain neurons. Comp. Neurol. (1994) 349:148–164.
   PubMed Web of Science ®Google Scholar
• CYTOTHERAPEUTICS, INC.: Press Release (March 26, 1996).
   Google Scholar
• CHANG TMS: Hybrid artificial cells: microencapsulation of living cells. ASAIO J. (1992) 38:128–130.
   PubMedGoogle Scholar
• WINN SR, TRESCO PA, ZELINSKY B etal.: Behavior recov-ery following intrastriatal implantation of microencap-sulated PC12 cells. Exp. Neurol. (1991) 113:322–329.
   Google Scholar
• BREM H, TAMARGO RJ, OLIVI A et al.: Biodegradable polymers for controlled delivery of chemotherapywith and without radiation therapy in the monkey brain. J. Neurosurg. (1994) 80:283–290.
   PubMed Web of Science ®Google Scholar
• GUILFORD PHARMACEUTICALS, INC.: Guilford Pharma-ceuticals licenses novel polymer drug delivery technol-ogy. PR Newswire (November 13, 1995).
   Google Scholar
• DEPOTECH CORPORATION: Company-sponsored stud-ies Phase III: Chiron/DepoTech DepoCyt. FDC Reports (September, 1995).
   Google Scholar
• B1NDSCHAEDLER C, LEONG K, MATHIOWITZ E, LANGER R: Polyanhydridle microsphere formulation by solvent extraction. J. Pharmacol. Sci. (1988) 77(8):696–698.
   Web of Science ®Google Scholar
• ELDRIDGE JH, STAAS JK, MEULBROEK JA, ncE TR, GP FY RM: Biodegradable and biocompatible poly(DL-lactid-co-glycolide) microspheres as an adjuvant for staphy-lococcal enterotoxin toxoid which enhances the level of toxin-neutralising antibodies. Infect. Immun. (1991) 59(9):2978–2986.
   PubMed Web of Science ®Google Scholar
• 'WILLIAMS LR, VARON S, PETERSON GM et al.: Continuous Infusion of nerve growth factor prevents basal fore-brain neuronal death after fimbria-fornix transection. Proc. Natl. Acad. Sci. USA (1986) 83:9231–9235.
   Google Scholar
• KOLIATSOS VE, CHATTERBUCK RE, GOURAS GK, PRICE DL: Biologic effects of nerve growth factor on lesioned basal forebrain neurons. Ann. NY Acad. Sci. (1991) 640:102–109.
   PubMed Web of Science ®Google Scholar
• KOL1ATSOS YE, CHA 1 t ERBUCK RE, NAUTA HJ et al.: Human nerve growth factor prevents degeneration of basal forebrain cholinergic neurons in primates. Ann. Neurol. (1991) 30(6):831–840.
   Google Scholar
• GLASS DJ, YANCOPOULOS GD: The neurotrophins and their receptors. Trends Cell Biol. (YEAR) 3:262–267.
   Google Scholar
• MORRRIS NP, CONSIGLIO E, KOHN LD et al.: Interaction of fragments B and C of tetanus toxin with neural and thyroid membranes and with gangliosicies. J. Biol. Chem. (1980) 255:6071–6076.
   PubMedGoogle Scholar
• DUMAS M, SCHWAB ME, TOENEN H: Retrograde axonal transport of specific macromolecules as a tool for characterising nerve terminal membranes. J. Neurobiol. (1979) 10(2):179–197. One of the earliest studies of retrograde transport with data on retrograde transport of NGF, WGA, tetanus toxin receptor binding fragment and cholera toxin subunit B (the binding domain of cholera toxin).
   Google Scholar
• COUNTER SA, ALDSKOGIUS H, BORG E: Cholera toxin B-HRP and wheat germ agglutinin-HRP tracing of tensor tympany muscle motorneurons and processes in rab-bits. Acta Otolaryrzgol. (Stockholm) (1993) 113:43–47.
   PubMed Web of Science ®Google Scholar
• SHONE CC, HAMBLETON P, MELLING J: Inactivation of Clostridium botulinum type A neurotoxin by trypsin and purification of two tryptic fragments. Eur. J. Bio-chem. (1985) 151:75–82.
   Web of Science ®Google Scholar
• BEISE J, HAHNEN J, ANDERSEN-BECKH B, DREYER F: Pore forming by tetanus toxin, its chain and fragments in neuronal membranes and evaluation of the underlying motifs in the structure of the toxin molecule. Naunyn-Schmiedeberg's Arch. Pharmacol. (1994) 349:66–73.
   Google Scholar
• MONTECUCCO C, PAPINI E, SCHIAVO G: Bacterial protein toxins penetrate cells via a four-step mechanism. FESS Lett. (1994) 346:92–98.
   PubMed Web of Science ®Google Scholar
• NISHI1U T-I, KAMATA Y, NEMOTO Y et al.: Identification of protein receptor for aostridium botulinum type B neurotoxin in rat synaptosomes. J. Biol. Chem. (1994) 269(14):10498–10503.
   Google Scholar
• KAMATA Y, KIMURA Y, HIROI T, SAKAGUCHI G, KOZAK" S: Purification and characterisation of the ganglioside-binding fragment of Clostridium botulinum type E neurotoxin. Biochim. Biophys. Acta (1993) 1156:213–218.
   PubMed Web of Science ®Google Scholar
• PASECHNIK VA, ELMORE M, MAUCHLINE ML et al.: Recom-binant expression in Escbericbia coil of a synthetic gene sub-fragment encoding the Hc polypeptide of type F botulinum neurotoxin: its potential as a vaccine. Abstracts of International Conference on Botulinum Toxin: Basic Science and Clinical Therapeutics. Munich (June 4–6, 1995). Movement Disorders (1995) 10(3):397.
   Google Scholar
• HALPERN JL, LOFTUS A: Characterisation of the receptorbinding domain of tetanus toxin. J. Biol. Chem. (1992) 268(15):11188–11192.
   Web of Science ®Google Scholar
• MECKLERRL, BARON R, MCLACHLAN EM: Selective uptakeof C-fragment of tetanus toxin by sympathetic pregan-glionic nerve terminals. Neuroscience (1990) 36(3):823–829.
   PubMed Web of Science ®Google Scholar
• JOBLING MG, HOLMES RK: Analysis of structure andfunction of the B subunit of cholera toxin by the use of site-directed mutagenesis. Mol. Microbiol. (1991) 5(7):1755–1767.
   PubMed Web of Science ®Google Scholar
• SPANGLER BD: Structure and function of cholera toxinand the related Escbericbia colt heat-labile entero-toxin. Microbiol. Rev. (1992) 56(4):622–647.
   PubMedGoogle Scholar
• PARDRIDGE WM: Recent advances in BBB transport. Ann. Rev, Pharmacol. Taxicol. (1988) 28:25–39.
   PubMed Web of Science ®Google Scholar
• FRIEDEN PM: Receptor-mediated transport of peptidesand proteins across the blood-brain barrier. In: The Blood-Brain Barrier. Partridge WM (Ed.), Raven Press, New York (1993).
   Google Scholar
• JEFFER1ES WA, BRANDON MR, HUNT SW et al.: Transfer-tin receptor on endothelium of brain capillaries. Nature (1984) 312(5990):162–163.
   Google Scholar
• DAUTRY-VARSAT A, CIECHANOVER A, LODISH HF: pHand recycling of transferrin during receptor-mediated endocytosis. Proc. Natl. Acad. Sci. USA (1983) 80:2258–2262.
   PubMed Web of Science ®Google Scholar
• FISHMAN JB, RUBIN JB, HANDRAHAN JV, CONNOR JR,FINE RE: Receptor-mediated transcytosis of transferrin across the blood-brain barrier. J. Neurosci. Res. (1987) 18:299–304.
   PubMed Web of Science ®Google Scholar
• PARDRIDGE WM et al.: Selective transport of an anti-transferrin receptor antibody through the blood-brain barrier in vivo. J. Pharmacol, Exp. Ther. (1991) 259:66–70.
   PubMed Web of Science ®Google Scholar
• FRIEDEN PM, WALUS RL, MUSSO GF et al.: Anti-transferrinreceptor antibody and antibody-drug conjugates cross the blood-brain barrier. Proc. Natl. Acad. Sci. USA (1991) 88:4771–4775.
   PubMed Web of Science ®Google Scholar
• TADAYONI BM, FRIEDEN PM, WALUS LR, MUSSO GM: Synthesis, in vitro kinetics and in vitro studies on protein conjugates of AZT: evaluation as a transport system to increase brain delivery. Bioconf. Chem. (1993) 4:139–145.
   PubMed Web of Science ®Google Scholar
• FRIEDEN PM, WALUS LR, WATSON P et al.: Blood-brainbarrier penetration and in vivo activity of an NGF conjugate. Science (1993) 259:373–377.
   PubMed Web of Science ®Google Scholar
• YASUNARI S, BUCIAK J, YANG J, PARDRIDGE WM: Vector- mediated delivery of 125I-labelled P-amyloid peptide Apt-4o through the blood-brain barrier and binding to Alzheimer disease amyloid of the A(3°/vector com-plex. Proc. Natl. Acad. Sci. USA (1995) 92:10227-10231. A first report on the use of antibody based protein carrier for deliverof 125i_ deliveringlabelled 13-amyloid peptide into the CNS fordeveloping a method of amyloid plaques detection in Alzheimer's disease.
   Google Scholar
• PARDRIDGE WM, KANG Y-S, BUCIAK JL, YANG J: HumanInsulin receptor monoclonal antibody undergoes high affinity binding to human brain capillaries in vitro and rapid transcytosis through the blood-brain barrier in vivo in the primate. Pharmac. Res. (1995)12:807–816.
   PubMed Web of Science ®Google Scholar
• TANIUCHI M, JOHNSON EM: Characterisation of the binding properties and retrograde axonal transport of a monoclonal antibody directed against the rat nerve growth factor receptor. J. Cell Biol. (1985) 101:1100–1106.
   PubMed Web of Science ®Google Scholar
• DISTEPHANO PS, SCHWEITZER JB, TANIUCHI M, JOHNSON EM, Jr.: Selective destruction of nerve growth factor receptor-bearing cells in vitro using a hybrid toxin composed of richt A chain and a monoclonal antibody against the nerve growth factor receptor. J. Cell. Biol. (1985) 1.01(3):1107–1114.
   Google Scholar
• DUFFY KR, PARDRLDGE WM: Blood-brain barrier tran-scytosis of insulin in developing rats. Brain Res. (1987) 420:32–38.
   PubMed Web of Science ®Google Scholar
• WAHLESTEDT C, PICH EM, KOOB GF, YEE F, HEILIG M:Modulation of anxiety and Neuropeptkle Y-Yl recep-tors by antisense oligonucleotides. Science (1993) 259:528–531.
   PubMed Web of Science ®Google Scholar
• PARTRIDGE WM, BOADO RJ, ICANG Y-S: Vector-mediateddelivery of a polyamide ('peptide') nucleic add ana-logue through the blood-brain barrier in vivo. Proc. NatL Acad. Sci. (1995) 92:5592–5596.
   PubMed Web of Science ®Google Scholar
• WAGNER E, ZENICE M, COTTEN M, BEUG H, BENSTIEL M:Transferrin-polycation conjugates as carriers for DNA uptake into cells. Proc. Natl. Acad. Sci. USA (1990) 87:3410–3414.
   PubMed Web of Science ®Google Scholar
• KAMATA H, YAGISAWA H, TAKAHASHI S, HIRATA H: Amphiphilic peptides enhance the efficiency of liposome-mediated DNA transfection. Nucleic Acid Res. (1994) 22:536–537.
   PubMed Web of Science ®Google Scholar
• GOTTSCHALK S, 1WEIEN RK, SMITH LC, WOO SL: Effi-cient gene delivery and expression in mammalian cells using DNA coupled with perfringolysin 0. Gene Ther. (1995) 2(7):498–503.
   PubMed Web of Science ®Google Scholar
• JANS DA: The regulation of protein transport to the nucleus by phosphorylation. Biochem.J. (1995) 311:705-716. A review article with a good presentation of transport mechanisms into the cell nucleus.
   Google Scholar
• CABOT JB: Sympathetic pregang,lionic neurons: cytoar-chitecture, ultrastructure, and biophysical properties. In: Central Regulations of Autonomic Functions. Loewy AD, Spyer KM (Eds.), Oxford University Press, New York (1990):44–67.
   Google Scholar
• MANNING KA, ERICHSEN JT, EVINGER C: Retrograde transneuronal transport properties of fragment C of tetanus toxin. Neuroscience (1990) 34(1):251–263.
   PubMed Web of Science ®Google Scholar
• OGUMA K, FUJINAGA Y, INOUE K: Structure and function of Clostridtum botulinum toxins. Microbiol. ImmunoL (1994) 39(3):161–168.
   Web of Science ®Google Scholar
• CRITCHLEY DR, PARDON RG, DAVIDSON MD, PIERCE EJ: Characterisation of tetanus toxin binding and internal-isation by neuronal tissue. In: Neurotaxins in Neurochem-istry. Dolly JO (Ed.), Ellis Horwood Limited, Chichester. 110–122.
   Google Scholar
• FISHMAN PS, SAVITT JM, FARRAND DA: Enhanced CNS uptake of systematically administered proteins through conjugation with tetanus C-fragment j Neurol. Studies (1990) 98:311–325.
   Google Scholar
• WELLER U, TAYLOR CF, HABERMAN E: Quantitative com-parison between tetanus toxin, some fragments and toxoid for binding and axon transport in the rat Toxicol. (1986) 24(11-12):1055–1063.
   Google Scholar
• EVIGER C, ERICHSEN JT: Transsynaptic retrograde trans-port of fragment C of tetanus toxin demonstrated by immunohistochemical localisation. Brain Res. (1986) 380:383–388.
   PubMed Web of Science ®Google Scholar
• CHIEN YW, CHANG S-F: Intranasal drug delivery for systemic medications. Crit . Rev. Ther. Drug Carrier Systems (1987) 4(2):67–194.
   PubMed Web of Science ®Google Scholar
• ALTAR CA, BAICHIT C: Receptor-mediated transport of human recombinant nerve growth factor from olfac-tory bulb to forebrain cholinergic nuclei. Brain R. (1991) 541(1):82–88.
   PubMed Web of Science ®Google Scholar
• PEARSON RCA, ESIRI M, HIORNS R, WILCOCK G, POWELL T: Anatomical correlates of the distribution of the pathological changes in the neocortex in Alzheimer disease. Proc. NatL Acad. Sci. (1985) 82:4531–4534.
   PubMed Web of Science ®Google Scholar
• TALAMO BR, RODEL R, KOSIK K: Pathological changes in olfactory neurons in patients with Alzheimer's disease. Nature (1989) 337:736–739.
   PubMed Web of Science ®Google Scholar
• FISHMAN PS, CARRIGAN DR: Motorneuron uptake from the drculation of the binding fragment of tetanus toxin. Arch. NeuroL (1988) 43:558–561.
   Google Scholar
• ESPARZA I, KISSEL T: Parameters affecting the hzununo-genicity of microencapsulated tetanus toxold. Vaccine (1992) 10(10):714–722.
   PubMed Web of Science ®Google Scholar
• FIGUEIREDO D, HALLEWELL R, CHEN LI et al.: Delivery of tetanus toxin fragment C-superoxide dismutase pro-teins to the CNS. International Conference on Biochemical Aspects of Clostridia! Neurotoxins. Oxford (July, 1996). Ab-stract 20.
   Google Scholar
• HAWGOOD B, BON C: Snake venom presynaptic toxins. •In: Handbook of Natural Toxins (Volume 5). Anthony TT (Ed.), Marcel Dekker, Inc., New York (1991):4–52.
   Google Scholar